OBX-115
- Generic Name
- OBX-115
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Tumor SkinLung CancerNon Small Cell Lung CancerMelanomaMetastatic Lung CancerMetastatic MelanomaMetastatic Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Obsidian Therapeutics, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT06060613
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸The Angeles Clinic and Research Institute (Melanoma), Los Angeles, California, United States
🇺🇸USC Norris Comprehensive Cancer Center (Melanoma/NSCLC), Los Angeles, California, United States
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
Phase 1
Active, not recruiting
- Conditions
- TumorMelanomaMetastatic Melanoma
- Interventions
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT05470283
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath